Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 2Neurofibroma 2Neurofibromatoses 1Neurofibroma, Plexiform 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Cancer 1

Interventions

Imatinib Mesylate 2tipifarnib 1nilotinib 1mirdametinib 1cabozantinib 1binimetinib 1Sunitinib 1Sevoflurane 1Propofol 1Percutaneous Collagen Induction 1Nitrous Oxide 1Lidocaine 1Glycopyrrolate 1Dexmedetomidine 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurofibromatoses × mirdametinib × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡